OrthoPediatrics Corp. (KIDS) Income Statement
KIDS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsKIDS revenue and net income
Where KIDS's revenue goes
2025Each bar shows an amount and its share of revenue. KIDS kept −16.8% of revenue as net income.
KIDS profit margins
KIDS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +15.4% | +24.6% | +27.2% | +22.5% |
| Gross profit | +16.2% | +24.0% | +25.7% | +23.1% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
KIDS quarterly EPS vs estimates
OrthoPediatrics beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: October 27, 2026 (estimate $-0.25).
KIDS income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $236.3M | $204.7M | $148.7M | $122.3M | $98.0M | $71.1M | $72.6M | $57.6M | $45.6M | $37.3M |
| Cost of revenue | $63.7M | $56.1M | $37.5M | $31.6M | $24.6M | $16.0M | $17.9M | $14.9M | $11.2M | $10.9M |
| Gross profit | $172.7M | $148.6M | $111.3M | $90.7M | $73.4M | $55.0M | $54.6M | $42.7M | $34.5M | $26.4M |
| Research & development | $9.1M | $11.0M | $10.9M | $8.5M | $5.5M | $5.3M | $5.7M | $4.7M | $3.4M | $2.2M |
| Sales, general & admin | $192.6M | $167.1M | $126.1M | $104.0M | $85.7M | $70.2M | $57.9M | $47.5M | $37.5M | $30.3M |
| Total operating expenses | $201.7M | $178.1M | $138.0M | $116.1M | $91.4M | $81.8M | $63.7M | $52.2M | $40.9M | $32.5M |
| Operating income | −$29.0M | −$29.5M | −$26.8M | −$25.4M | −$18.0M | −$26.8M | −$9.1M | −$9.6M | −$6.5M | −$6.1M |
| Interest income | — | — | — | — | — | — | $3.5M | $2.3M | $2.5M | $1.5M |
| Interest expense | $6.0M | $2.6M | $198,000 | $2.4M | $2.2M | $3.4M | $3.5M | $2.3M | $2.5M | $1.5M |
| Income before taxes | −$39.2M | −$41.9M | −$21.3M | −$3.7M | −$17.4M | −$33.7M | −$12.7M | −$12.0M | −$8.9M | −$6.6M |
| Income taxes | $460,000 | −$4.1M | −$338,000 | −$4.9M | −$1.1M | −$723,000 | $4.5M | −$217,000 | $2.5M | $2.5M |
| Net income | −$39.6M | −$37.8M | −$21.0M | $1.3M | −$16.3M | −$32.9M | −$13.7M | −$12.0M | −$8.9M | −$6.6M |
| EBITDA | −$12.1M | −$20.2M | −$8.4M | −$8.7M | −$7.2M | −$22.2M | −$4.5M | −$6.9M | −$4.0M | −$3.2M |
| EPS (diluted) | −$1.00 | −$1.04 | −$0.84 | −$0.87 | −$0.75 | −$1.71 | −$0.87 | −$0.96 | −$4.18 | −$0.87 |
| Gross margin | 73.1% | 72.6% | 74.8% | 74.1% | 74.9% | 77.4% | 75.3% | 74.2% | 75.5% | 70.7% |
| Operating margin | −12.3% | −14.4% | −18.0% | −20.8% | −18.4% | −37.6% | −12.5% | −16.6% | −14.2% | −16.4% |
| Net margin | −16.8% | −18.5% | −14.1% | 1.0% | −16.6% | −46.3% | −18.9% | −20.9% | −19.6% | −17.6% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $70.5M | $59.4M | $61.6M | $61.2M | $61.1M | $52.4M | $52.7M | $54.6M | $52.8M | $44.7M | $37.6M | $40.0M |
| Cost of revenue | $18.1M | $16.0M | $16.5M | $16.0M | $17.1M | $14.1M | $17.1M | $14.5M | $12.0M | $12.5M | $10.9M | $9.0M |
| Gross profit | $52.4M | $43.4M | $45.1M | $45.3M | $44.0M | $38.3M | $35.6M | $40.1M | $40.8M | $32.2M | $26.7M | $31.0M |
| Research & development | $2.3M | $2.2M | $2.3M | $2.3M | $2.2M | $2.4M | $2.9M | $2.6M | $2.5M | $3.0M | $2.7M | $2.6M |
| Sales, general & admin | $54.1M | $49.5M | $48.4M | $47.8M | $49.5M | $46.9M | $41.2M | $43.0M | $43.9M | $38.9M | $32.0M | $31.9M |
| Total operating expenses | $56.4M | $51.7M | $50.6M | $50.1M | $54.7M | $49.2M | $49.6M | $45.6M | $46.5M | $41.9M | $34.8M | $35.5M |
| Operating income | −$4.1M | −$8.3M | −$5.5M | −$4.9M | −$10.7M | −$11.0M | −$14.1M | −$5.6M | −$5.7M | −$9.7M | −$8.1M | −$4.5M |
| Interest expense | $2.5M | $2.1M | $1.9M | $1.8M | $1.1M | $1.1M | $1.3M | $404,000 | $261,000 | $637,000 | $303,000 | $21,000 |
| Income before taxes | −$6.9M | −$10.9M | −$9.8M | −$11.9M | −$7.1M | −$10.5M | −$16.4M | −$9.1M | −$6.0M | −$10.3M | −$6.9M | −$3.7M |
| Income taxes | $234,000 | −$171,000 | $340,000 | −$125,000 | $49,000 | $196,000 | −$340,000 | −$1.2M | −$18,000 | −$2.5M | −$212,000 | $849,000 |
| Net income | −$7.2M | −$10.7M | −$10.1M | −$11.8M | −$7.1M | −$10.7M | −$16.1M | −$7.9M | −$6.0M | −$7.8M | −$6.7M | −$4.6M |
| EBITDA | $1.3M | −$3.0M | $2.0M | −$4.8M | −$778,000 | −$4.3M | −$4.6M | −$3.5M | −$1.0M | −$4.7M | −$6.3M | $549,000 |
| EPS (diluted) | −$0.26 | −$0.42 | −$0.26 | −$0.24 | −$0.11 | −$0.39 | −$0.29 | −$0.18 | −$0.23 | −$0.34 | −$0.23 | −$0.13 |
| Gross margin | 74.3% | 73.1% | 73.2% | 73.9% | 72.1% | 73.0% | 67.5% | 73.4% | 77.3% | 72.0% | 71.0% | 77.4% |
| Operating margin | −5.8% | −14.0% | −8.9% | −7.9% | −17.4% | −21.0% | −26.7% | −10.2% | −10.7% | −21.8% | −21.4% | −11.3% |
| Net margin | −10.2% | −18.0% | −16.4% | −19.2% | −11.6% | −20.3% | −30.5% | −14.5% | −11.4% | −17.5% | −17.8% | −11.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in KIDS's financial statements (latest annual report filed March 4, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
KIDS financial results
In fiscal year 2025 (ended December 31, 2025), OrthoPediatrics reported revenue of $236.3 million, up 15.4% from the year before. It had a net loss of $39.6 million, a net profit margin of −16.8%. Diluted earnings per share came to −$1.00. Over five years revenue grew at an average rate of 27.2% a year.
See the KIDS stock overview for the latest quote and news, or the KIDS chart for price history and technical indicators.
KIDS income statement FAQ
What is OrthoPediatrics's annual revenue?
OrthoPediatrics reported total revenue of $236.3 million for fiscal year 2025, which ended on December 31, 2025. That was up 15.4% from $204.7 million the previous year.
Is OrthoPediatrics profitable?
No. OrthoPediatrics reported a net loss of $39.6 million in fiscal 2025, a net profit margin of −16.8%; its operating margin was −12.3%.
What is OrthoPediatrics's gross margin?
OrthoPediatrics's gross margin was 73.1% in fiscal 2025: for every $100 of revenue, OrthoPediatrics kept $73 after the direct cost of its products and services.
How much does OrthoPediatrics spend on research and development?
OrthoPediatrics spent $9.1 million on research and development in fiscal 2025, 3.9% of revenue.
How fast is OrthoPediatrics growing?
Revenue grew 27.2% a year on average over the last five fiscal years, from $71.1 million to $236.3 million.
What are OrthoPediatrics's earnings per share?
OrthoPediatrics earned $-1.00 per diluted share in fiscal 2025, compared with $-1.04 a year earlier.
When will OrthoPediatrics report its next earnings?
OrthoPediatrics is expected to report results for the quarter ending September 30, 2026 on October 27, 2026 after the market closes.
When does OrthoPediatrics's fiscal year end?
OrthoPediatrics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 4, 2026.